Exelixis climbs as pipeline catalysts and 2026 outlook refocus attention on growth
Exelixis shares rose after investors focused on its 2026 revenue outlook and upcoming mid-2026 pivotal readouts for zanzalintinib, a potential second commercial franchise beyond Cabometyx. The company has also highlighted an active capital-return program, including a $750 million repurchase authorization running through Dec. 31, 2026.
1. What’s driving the move
Exelixis (EXEL) traded higher as market attention rotated back to the company’s 2026 growth setup: a reaffirmed revenue outlook centered on continued Cabometyx momentum and a pipeline calendar led by multiple zanzalintinib ("zanza") pivotal trials. With several mid-2026 trial milestones on the horizon, traders appeared to be positioning for a catalyst-heavy stretch rather than reacting to a single same-day headline. (ir.exelixis.com)
2. The fundamental backdrop investors are leaning on
Exelixis has guided to 2026 total revenues of $2.525–$2.625 billion (and net product revenues of $2.325–$2.425 billion), reinforcing expectations that the base business can fund pipeline expansion. Separately, the company has emphasized shareholder returns, including a $750 million repurchase authorization extending through December 31, 2026, which can act as a technical support for the stock during quieter news periods. (ir.exelixis.com)
3. Near-term catalysts and what could change sentiment
The next major narrative swing factor is clinical execution for zanzalintinib. Exelixis has pointed investors to mid-2026 timing for topline results from STELLAR-304 and has also framed STELLAR-303 as a key program supporting its regulatory path in colorectal cancer, where the FDA is reviewing the NDA for zanzalintinib in combination with atezolizumab and the disclosed target action date is Dec. 3, 2026. Any updates to event-rate timing, safety, or comparative efficacy versus standard-of-care could quickly reprice expectations for a second franchise beyond cabozantinib. (ir.exelixis.com)